Verdence Capital Advisors’s Idexx Laboratories IDXX Stock Holding History

Verdence Capital Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$816K	Buy	1,452 +101	+7%	+$64.8K	0.05%	330
2025 Q4	$914K	Sell	1,351 -320	-19%	-$218K	0.05%	296
2025 Q3	$1.08M	Buy	1,671 +168	+11%	+$102K	0.06%	295
2025 Q2	$806K	Buy	+1,503	New	+$719K	0.06%	296
2022 Q4	–	Sell	-1,147	Closed	-$374K	–	527
2022 Q3	$374K	Buy	1,147 +41	+4%	+$15.1K	0.05%	326
2022 Q2	$388K	Buy	1,106 +719	+186%	+$293K	0.05%	323
2022 Q1	$212K	Buy	387 +12	+3%	+$6.31K	0.02%	486
2021 Q4	$247K	Buy	375 +7	+2%	+$4.39K	0.03%	452
2021 Q3	$229K	Buy	+368	New	+$247K	0.03%	446

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Verdence Capital Advisors's IDXX Position: Q1 2026 in Review

Verdence Capital Advisors increased its Idexx Laboratories (IDXX) stake by 7.5% in Q1 2026, buying an estimated $64.8K and bringing the position to 1,452 shares worth $816K. The position accounts for 0.05% of the portfolio, ranked #330.

Verdence Capital Advisors first reported a position in IDXX in Q3 2021 and has held it in 9 quarters since. The position peaked at $1.08M in Q3 2025. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

Verdence Capital Advisors held 1,452 shares of Idexx Laboratories worth $816K as of Q1 2026.
Verdence Capital Advisors bought 101 Idexx Laboratories shares in Q1 2026, an estimated $64.8K.
Idexx Laboratories made up 0.05% of Verdence Capital Advisors's portfolio in Q1 2026, its #330 holding.
Verdence Capital Advisors first reported a position in Idexx Laboratories in Q3 2021 and has held it in 9 quarters since.
Verdence Capital Advisors's Idexx Laboratories position peaked at $1.08M in Q3 2025.
1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Verdence Capital Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.